期刊
EXPERT OPINION ON THERAPEUTIC TARGETS
卷 11, 期 3, 页码 321-336出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.11.3.321
关键词
arrhythmia; dysrhythmia; hERG; K+ channel; KCNH2; K(v)11. 1; Torsades de pointes
The hERG (human ether-a-go-go-related gene) potassium channel has elicited intense scientific interest due to its counter-intuitive kinetics and its association with arrhythmia and sudden death. hERG blockade is involved in both antiarrhythmic pharmacotherapy and the pathogenesis of familial and acquired long QT syndrome (LQTS). Short QT syndrome (SQTS), muscular atrophy and many forms of cancer have also been associated with hERG as a target. Molecular models of both the channel and its blocker pharmacophores exist, revealing methods to design hERG liability out of potential drug molecules. Future developments will synthesise preclinical data on hERG with other criteria to determine net arrhythmogenic risk. Also, the molecular actions of hERG and its genetics will be elucidated in detail to allow clinical risk reduction.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据